FOLD Stock Cash Flow Statements

Amicus Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Amicus Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-03-31

operating activities
net income	-24,420,000	-21,686,000	14,739,000	-6,729,000	-15,697,000	-48,419,000	-33,843,000	-21,577,000	-43,232,000	-52,932,000	-55,865,000	-33,286,000	-62,157,000	-85,260,000	-83,277,000	-50,294,000	-51,225,000	-65,664,000	-71,401,000	-64,011,000	-52,492,000	-88,948,000	-89,729,000	-61,809,000	-84,551,000	-120,299,000	-78,081,000	-159,163,000	-61,835,000	-49,916,000	-111,665,000	-48,137,000	-54,992,000	-43,691,000
adjustments to reconcile net income to net cash from operating activities:
amortization of debt discount and deferred financing	630,000	606,000	597,000	574,000	560,000	531,000	536,000	721,000	692,000	667,000	671,000	668,000	658,000	637,000	638,000	652,000	645,000	555,000	670,000	592,000	301,000	231,000	256,000	186,000	455,000	1,649,000	3,108,000	2,595,000	2,672,000	2,601,000
depreciation and amortization	1,852,000	1,837,000	2,041,000	2,170,000	2,182,000	2,154,000	2,182,000	2,228,000	2,206,000	1,257,000	1,311,000	1,286,000	1,334,000	1,411,000	1,518,000	1,520,000	1,567,000	1,604,000	2,547,000	2,496,000	2,039,000	1,764,000	1,514,000	1,116,000	1,154,000	991,000
stock-based compensation	17,559,000	25,172,000	19,217,000	18,688,000	16,197,000	30,803,000	18,095,000	16,511,000	16,577,000	34,894,000		14,772,000	12,463,000	30,651,000	13,907,000	11,841,000	11,736,000	20,354,000	12,239,000	15,908,000	8,408,000	12,596,000	12,908,000	8,843,000	9,935,000	12,744,000	8,387,000	7,054,000	6,341,000	7,478,000	5,500,000	5,537,000	6,030,000	4,283,000
foreign currency remeasurement (gain) loss	4,111,000	-5,356,000																								325,000
other	2,794,000	1,175,000		528,000	702,000	5,818,000																	-13,000
changes in operating assets and liabilities:
accounts receivable	-12,492,000	15,330,000	-10,394,000	-8,643,000	-10,004,000	9,557,000	-11,494,000	-11,319,000	4,072,000	-1,367,000	-9,904,000	-3,002,000	-3,424,000	-1,000,000	-1,817,000	-3,245,000	-3,966,000	839,000	-374,000	-457,000	-2,030,000	-8,358,000	1,530,000	-5,815,000	-5,828,000	-1,001,000	-8,112,000	861,000
inventories	-22,577,000	-8,288,000	-12,020,000	-34,731,000	-25,223,000	-1,678,000	-2,381,000	-14,750,000	-24,325,000	-3,158,000	-10,256,000	1,376,000	1,725,000	1,812,000	-4,768,000	1,423,000	-5,186,000	741,000	-6,821,000	831,000	1,602,000	-251,000	-3,098,000	-108,000	-2,253,000	345,000	-2,156,000	1,400,000
prepaid expenses and other current assets	-4,754,000	-3,603,000	-14,255,000	14,257,000	19,299,000	-5,340,000	17,948,000	-13,747,000	-14,102,000	1,839,000	-611,000	-1,102,000	-7,813,000	3,332,000	-14,999,000	3,815,000	-2,404,000	7,669,000	-13,143,000	3,002,000	-2,641,000	4,016,000	34,000	202,000	-6,582,000	3,059,000	-145,000	-1,951,000	-6,291,000	10,875,000
accounts payable, accrued expenses, and other current liabilities	10,360,000	3,647,000	-5,037,000	-14,124,000	27,124,000	-24,483,000	8,094,000	9,481,000	31,692,000	-72,000	-31,842,000	2,794,000	37,234,000	-14,563,000
other non-current assets and liabilities	411,000	-1,076,000	-2,033,000	-737,000	-104,000	-374,000	1,939,000	-2,407,000	-2,192,000	-394,000	1,306,000	-3,180,000	-1,326,000	-1,436,000	-447,000	-386,000	-206,000	-1,578,000	6,684,000	-1,233,000	4,303,000	-5,334,000	-12,081,000	2,783,000	2,688,000	-3,507,000
net cash from operating activities	-26,526,000	7,758,000	-3,916,000	-22,971,000	22,691,000	-29,695,000	3,458,000	-38,347,000	-16,133,000	-18,069,000	-80,772,000	-11,626,000	-15,862,000	-58,315,000	-70,514,000	-23,700,000	-35,923,000	-72,354,000	-49,822,000	-42,008,000	-33,518,000	-107,942,000	-57,832,000	-55,553,000	-58,485,000	-78,546,000	-60,677,000	-132,762,000	-56,995,000	-49,521,000
investing activities
sale and redemption of marketable securities	10,995,000	6,161,000	15,904,000	39,540,000	23,428,000	38,907,000	16,399,000	53,980,000	71,904,000	54,944,000	76,006,000	75,859,000	75,733,000	108,328,000	81,700,000	83,576,000	95,087,000	163,680,000	82,147,000	62,540,000	103,999,000	106,140,000	109,805,000	127,817,000	126,238,000	135,187,000	75,367,000	177,896,000	89,013,000	121,226,000	93,072,000	68,466,000	69,443,000	53,157,000
purchases of marketable securities	-14,370,000	-38,810,000	-36,008,000	-4,912,000	-44,307,000	-29,559,000	-38,625,000	-16,650,000	-19,701,000	-16,747,000	-143,444,000	-1,481,000	-49,086,000	-49,244,000	-148,029,000	-48,114,000	-69,008,000	-76,247,000	-103,856,000	-216,317,000	-32,917,000	-12,088,000	-71,917,000	-120,647,000	-139,140,000	-52,178,000	-137,431,000	-60,729,000
capital expenditures	-2,403,000	-212,000	-288,000	-356,000	-1,098,000	-1,811,000	-1,731,000	-1,565,000	-2,202,000	-1,942,000	-2,677,000	137,000	-355,000	-871,000	-1,760,000	-890,000	-366,000	-868,000	-1,067,000	-284,000	-1,070,000	-806,000	-10,925,000	-3,977,000	-2,166,000	-2,944,000	-1,737,000	-2,690,000
free cash flows	-28,929,000	7,546,000	-4,204,000	-23,327,000	21,593,000	-31,506,000	1,727,000	-39,912,000	-18,335,000	-20,011,000	-83,449,000	-11,489,000	-16,217,000	-59,186,000	-72,274,000	-24,590,000	-36,289,000	-73,222,000	-50,889,000	-42,292,000	-34,588,000	-108,748,000	-68,757,000	-59,530,000	-60,651,000	-81,490,000	-62,414,000	-135,452,000
net cash from investing activities	-5,778,000	-32,861,000	-20,392,000	34,272,000	-21,977,000	7,537,000	-23,957,000	35,765,000	50,001,000	36,255,000	-66,704,000	74,515,000	26,292,000	58,213,000	-68,089,000	34,572,000	25,713,000	86,565,000	-22,776,000	-154,061,000	70,012,000	93,246,000	26,963,000	3,193,000	-15,068,000	80,065,000	-63,801,000	114,477,000	10,727,000	-182,603,000
financing activities
payment of finance leases	-8,000	-15,000	-43,000	24,000	-36,000	-42,000	-193,000	-31,000	-23,000	-28,000	-191,000	-51,000	-21,000	-20,000	-19,000	-71,000	-21,000	-368,000	-18,000	-20,000	-17,000	-21,000	-243,000	-79,000	-23,000	-75,000
withholding taxes paid on vested restricted stock units	-432,000	-11,790,000	-828,000	-2,792,000	-1,684,000	-16,721,000	-1,565,000	-2,347,000
proceeds from stock options exercised	40,000	105,000	1,555,000	1,805,000	863,000	3,454,000	2,414,000	3,442,000	1,750,000	2,655,000	1,119,000	1,333,000	999,000	859,000	1,871,000	1,696,000
net cash from financing activities	-400,000	-11,700,000	1,097,000	18,190,000	-857,000	-13,309,000	8,210,000	37,619,000	23,673,000	-7,825,000	557,000	-559,000	693,000	-8,154,000	-104,000	201,113,000	2,235,000	8,829,000	21,548,000	238,711,000	4,086,000	-1,487,000	3,191,000	523,000	196,404,000	17,384,000	359,000	146,804,000	7,033,000	296,579,000
effect of exchange rate changes on cash, cash equivalents, and restricted cash	9,987,000	4,819,000	3,107,000	-5,028,000	-294,000	-1,816,000	-3,906,000	16,902,000	-8,191,000	1,507,000	18,501,000	-20,658,000	-9,085,000	-3,377,000	-908,000	-2,702,000	-286,000	-1,153,000	3,785,000	3,521,000	789,000	-4,265,000	4,320,000	-1,650,000
net decrease in cash, cash equivalents, and restricted cash at the end of the period	-22,717,000	-31,984,000
cash, cash equivalents, and restricted cash at the beginning of period	0	216,716,000		0	0	250,077,000		0	0	153,115,000		0	0	249,456,000
cash, cash equivalents, and restricted cash at the end of period	-22,717,000	184,732,000		24,463,000	-437,000	212,794,000		51,939,000	49,350,000	164,983,000		41,672,000	2,038,000	237,823,000		209,283,000	-8,261,000	188,049,000		46,163,000	41,369,000	125,893,000
supplemental disclosures of cash flow information
cash paid during the period for interest	10,942,000	10,852,000		23,797,000	11,989,000	11,801,000		12,293,000	11,794,000	11,361,000		8,950,000	7,599,000	7,509,000		7,679,000	7,596,000	7,513,000		6,003,000	7,016,000	3,693,000		3,843,000	4,456,000	4,846,000	3,713,000	13,000	3,762,000	12,000	12,000	3,638,000	12,000
cash paid for taxes	354,000	377,000		1,603,000	491,000	635,000		495,000	5,800,000	178,000		225,000	254,000	456,000		5,328,000	2,054,000	2,472,000
supplemental disclosure of non-cash investing and financing activities
tenant improvements paid through lease incentives	98,000	97,000		97,000	68,000	52,000										0				15,000	201,000	254,000
capital expenditures unpaid at the end of period	36,000	138,000		78,000	-1,020,000	1,110,000		580,000	-963,000	1,260,000		0	-19,000	72,000		136,000	3,000	188,000		-237,000	-87,000	589,000
cashless exercise of warrants	0	71,000
loss on extinguishment of debt															0				0
non-cash changes in the fair value of contingent consideration payable							0	1,995,000	337,000	251,000	1,584,000	567,000	115,000	-1,188,000	1,734,000	3,288,000	1,021,000	471,000	464,000	1,034,000	715,000	931,000	645,000	789,000	480,000	1,383,000	600,000	1,300,000	300,000	1,100,000		1,050,000	4,578,000	3,152,000
foreign currency remeasurement loss			1,067,000	5,776,000	7,655,000	1,736,000	1,492,000	-5,783,000	18,019,000	5,885,000	3,293,000	2,475,000	-320,000	673,000			389,000	2,846,000	6,555,000	-6,688,000	-5,058,000	10,662,000		2,135,000
non-cash deferred taxes																																49,000	49,000
asset impairment charges and other asset write-offs							367,000	300,000			906,000	5,006,000
payment of contingent consideration							-13,410,000	0
proceeds from sale of assets
proceeds from the issuance of shares in connection with at-the-market offering, net of issuance costs			413,000				0	36,555,000	24,199,000	2,354,000
proceeds from equity financing, net of issuance costs
proceeds from warrants exercised							0	0							0	0
payment of long-term debt																			0
proceeds from long-term debt, net of issuance costs																			0
net increase in cash, cash equivalents, and restricted cash																							-23,358,000	-53,487,000
cash, cash equivalents, and restricted cash at the beginning of the year
cash, cash equivalents, and restricted cash at the end of the year
deferred taxes								0	0	-4,939,000
net increase in cash, cash equivalents, and restricted cash at the end of the period				24,463,000	-437,000	-37,283,000		51,939,000	49,350,000	11,868,000		41,672,000	2,038,000	-11,633,000		209,283,000				46,163,000	41,369,000	-20,448,000
purchase of vested restricted stock units, net of taxes										-12,806,000	-371,000	-1,841,000	-285,000	-8,993,000
share-based compensation
proceeds from issuance of common stock from equity financing and pre-funded warrants, net of issuance costs
loss on impairment of assets														6,616,000
loss on exchange of convertible notes
deferred reimbursements																			0				-4,000,000	0	0	-1,500,000
proceeds from issuance of common stock, net of issuance costs																								0				0	0	294,584,000
payments of employee withholding taxes related to restricted stock unit vesting															-309,000	-262,000
proceeds from termination of capped call confirmations																							0	0	5,243,000	14,632,000
foreign currency remeasurement gain
accounts payable and accrued expenses																6,417,000	11,706,000	-40,191,000		492,000	11,335,000	-35,251,000		-3,739,000	21,311,000	-8,858,000
proceeds from issuance of common stock from equity financing and pre-funded warrants
cash, cash equivalents, and restricted cash at beginning of period																0	0	166,162,000		0	0	146,341,000		0
purchase of vested restricted stock units																		-14,194,000	-688,000	-1,243,000	-554,000	-7,543,000	-234,000	-446,000	-617,000	-1,938,000	-151,000	-654,000
proceeds from exercise of stock options																		4,161,000	22,254,000	9,294,000	4,657,000	6,077,000	3,668,000	1,048,000	2,807,000	3,953,000	652,000	912,000	3,602,000	3,978,000	7,287,000	1,289,000	265,000	155,000
proceeds from exercise of warrants																		19,230,000									0
net increase(decrease) in cash, cash equivalents, and restricted cash at the end of the period																		21,887,000
change in fair value of derivatives																											0	0
loss on exchange of convertible debt																							0	0	4,501,000	36,123,000
proceeds of exercise of warrants																								0	0	812,000
contingent consideration paid in shares
loss on impairment
proceeds from issuance of common stock and warrants, net of issuance costs
proceeds from loan agreements, net of issuance costs
proceeds from senior secured term loan
cash, cash equivalents, and restricted cash at end of period																								-53,487,000
capital expenditures, unpaid																								1,965,000						142,000
payment of contingent consideration in shares																								0	0	9,316,000
capital expenditures funded by capital lease																												-1,000
effect of exchange rate changes on cash, cash equivalents and restricted cash																										-2,350,000	2,664,000	-130,000
net decrease in cash, cash equivalents and restricted cash																										16,553,000
cash, cash equivalents and restricted cash at beginning of period																										82,375,000
cash, cash equivalents and restricted cash at end of period																										98,928,000
depreciation																											1,201,000	1,073,000	973,000	969,000	850,000	813,000	823,000	673,000
restructuring charges																																		50,000
charges to research expense for stock issued in asset acquisition
(gain) loss on disposal of assets
other non-current assets																											62,000	-308,000
account payable and accrued expenses																											13,431,000	15,485,000
non-current liabilities																											-223,000	224,000	237,000	220,000	141,000	133,000	363,000	380,000
payments of secured loan agreement
payment of capital leases																											-116,000	-76,000
proceeds from issuance of convertible notes, net of issuance costs
premiums paid for capped call confirmations
net increase in cash and cash equivalents and restricted cash																											-121,455,000	128,389,000	-41,111,000	65,315,000
cash and cash equivalents and restricted cash at beginning of year/period
cash and cash equivalents and restricted cash at end of year/period
capital expenditures funded by capital lease borrowings
gain on disposal of asset
foreign currency remeasurement (gain)/ loss																												-1,332,000
deferred reimbursement																												0
proceeds from senior secured term loan, net of issuance costs
payment of deferred financing fees
cash and cash equivalents and restricted cash at beginning of period																												0	0	51,237,000
cash and cash equivalents and restricted cash at end of period																												128,389,000	-41,111,000	116,552,000
effect of exchange rate changes on cash and cash equivalents and restricted cash																														860,000
(gain)/ loss on disposal of asset
change in fair value of derivative liability
non-cash deferred taxes and other tax benefits
purchases of property and equipment
proceeds from unsecured loan agreement
effect of exchange rate changes on cash and cash equivalents																															416,000	534,000	80,000
net decrease in cash and cash equivalents
cash and cash equivalents at beginning of year/ period																															0	0	187,026,000
cash and cash equivalents at end of year/period																															26,739,000	-7,361,000	44,755,000
contingent consideration resolution in shares
non-cash interest expense																																2,312,000	2,403,000	451,000
non-cash income tax benefit
net cash used in/ (provided by) financing activities
capital expenditures unpaid at end of the period
loss on disposal of asset
non-cash changes in the fair value of derivative liability
acquisitions, net cash of acquired
proceeds from unsecured note agreement
proceeds from related party
payment of capital lease
cash and cash equivalents at beginning of period																																		69,485,000
cash and cash equivalents at end of period																																		23,510,000
net cash (used in)/ provided by investing activities
net (decrease)/ increase in cash and cash equivalents
net cash (used in)/ provided by financing activities
receivable due from collaboration agreements
net cash (used in) investing activities
net increase/(decrease) in cash and cash equivalents
net cash provided by/(used in) investing activities
net cash provided by/(used in) financing activities
change in fair value of warrant liability
net cash (used in)/provided by financing activities
non-cash activities
amortization of non-cash compensation
non-cash charge for stock based compensation issued to consultants
stock-based license payments
impairment of leasehold improvements
non-cash charge for in-process research and development
beneficial conversion feature related to bridge financing
receivable due from gsk
proceeds from the issuance of preferred stock, net of issuance costs
proceeds from the issuance of common stock and warrants, net of issuance costs
proceeds from the issuance of convertible notes
payments of capital lease obligations
payments related to deferred financing
proceeds from capital asset financing arrangement
proceeds from secured loan agreement
net (decrease)/increase in cash and cash equivalents
stock-based compensation - employees
stock-based compensation - non-employees
redemption of marketable securities
proceeds from secured loan arrangement
net cash provided by/ (used in) financing activities
receivable from gsk
net cash (used in)/provided by investing activities
deferred revenue
stock-based license payment
non-cash charge for in process research and development
conversion of preferred stock to common stock
conversion of notes payable to series b redeemable convertible preferred stock
accretion of redeemable convertible preferred stock
beneficial conversion feature related to issuance of the additional issuance of series c redeemable convertible preferred stock
stock-based compensation — employees
stock-based compensation — non-employees
debt instrument convertible beneficial conversion feature
adjustments to reconcile net income to net cash (used in)/provided by operating activities:
net cash provided by/(used in) operating activities
proceeds from the issuance of common stock, net of issuance costs
conversion of notes payable to preferred stock
beneficial conversion feature related to the issuance of series c redeemable convertible preferred stock
net increase in cash and cash equivalents
beneficial conversion feature related to issuance of the second tranche of series c redeemable convertible preferred stock

We provide you with 20 years of cash flow statements for Amicus Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Amicus Therapeutics stock. Explore the full financial landscape of Amicus Therapeutics stock with our expertly curated income statements.

The information provided in this report about Amicus Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.